CCA
VCNX

Catalyst Capital Advisors’s Vaccinex, Inc. Common Stock VCNX Stock Holding History

Catalyst Capital Advisors’s Portfolio VCNX Stock Details VCNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2
Closed -$3K – 504
2018
Q3 		$3K Buy
+2
New +$4.13K ﹤0.01% 437

Other funds holding VCNX

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Catalyst Capital Advisors's VCNX Position: Q4 2018 in Review

Catalyst Capital Advisors sold out of Vaccinex, Inc. Common Stock (VCNX) in Q4 2018, closing a stake of 2 shares — an estimated $3K sold.

Catalyst Capital Advisors first reported a position in VCNX in Q3 2018 and held it in 1 quarter. The position peaked at $3K in Q3 2018. 11 funds tracked by Wall St. Rank hold VCNX as of Q4 2018.

  • Catalyst Capital Advisors reported no remaining Vaccinex, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 2 Vaccinex, Inc. Common Stock shares in Q4 2018, an estimated $3K.
  • Catalyst Capital Advisors first reported a position in Vaccinex, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Catalyst Capital Advisors's Vaccinex, Inc. Common Stock position peaked at $3K in Q3 2018.
  • 11 funds tracked by Wall St. Rank held Vaccinex, Inc. Common Stock as of Q4 2018.

Based on Catalyst Capital Advisors's 13F filing for Q4 2018, filed 7 Feb 2019.